1 **Scientific Commentary**

2 **Neurofilament light chain - defining the analyte**

3

4 Claire A. Leckey[1,2,3], Henrik Zetterberg[1,2,4,5,6]∗

5

6 [1] UK Dementia Research Institute at UCL, London, UK

7 [2] Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK

8 [3] Centre for Translational Omics, UCL Great Ormond Street Institute of Child Health, London, UK

9 [4] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska
10 Academy at University of Gothenburg, Mölndal, Sweden

11 [5] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

12 [6] Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China

13

14 *Correspondence to:

15 Henrik Zetterberg, UKDRI Fluid Biomarker Laboratory, Wing 2.3 Cruciform Building, Gower Street,
16 London, WC1E 6BT, United Kingdom

17 E-mail: h.zetterberg@ucl.ac.uk

18

1 **This scientific commentary refers to 'A map of neurofilament light chain species in brain and**
2 **cerebrospinal fluid and alterations in Alzheimer's disease' by Budelier *et al*.**
3 **(**https://doi.org/10.1093/braincomms/fcac045)

4 In 1996, Lars Rosengren,[1] a histologist and neurologist at Sahlgrenska University Hospital, Gothenburg,
5 Sweden, published the first enzyme-linked immunosorbent assay (ELISA) to measure neurofilament light
6 chain (NfL) concentration in human cerebrospinal fluid (CSF) using polyclonal antibodies. He and his
7 team reported higher NfL concentration in CSF samples from patients with amyotrophic lateral sclerosis
8 and Alzheimer's disease (AD) compared with controls. Pilot data on increased CSF NfL concentration in
9 vascular dementia, olivopontocerebellar atrophy, normal pressure hydrocephalus, cerebral infarctions
10 and multiple sclerosis were also presented.[1] Since then, NfL has emerged as an intriguing and clinically
11 meaningful fluid-based biomarker of neuronal axonal injury and degeneration that is elevated in
12 multiple neurodegenerative diseases,[2] as well as in neuroinflammation,[3] CNS infections,[4] and acute
13 brain injury.[5] Currently, these studies have focused on its quantitation by immunoassay-based methods,
14 which have offered the analytical sensitivity required to measure and compare NfL levels in CSF (by
15 ELISA), as well as plasma and serum (by Single molecule array or Meso Scale Discovery technology),
16 across various neurodegenerative disease cohorts. Remarkably, characterisation of the exact species of
17 NfL that are present in CSF and being measured has remained a pressing question that has been left
18 unanswered.

19 Given the clinical utility of the marker, as well as its use in clinical trials to detect disease-modifying
20 effects of novel treatments against brain diseases, standardising NfL assays to each other would be
21 valuable. To this end, certified reference materials that have been value-assigned using certified
22 reference methods are needed. However, a pre-requisite for this type of work is detailed knowledge on
23 the exact form of the analyte to be measured.

24 In this issue of *Brain Communications*, Budelier and colleagues[6] present the development and validation
25 of a hybrid immunoprecipitation-mass spectrometry (IP-MS) method combined with tryptic digestion to
26 characterise and quantify NfL in brain tissue and CSF. Using 23 custom antibodies generated against
27 different domains of the full protein sequence, the authors initially identified NfL fragments in brain
28 tissue and CSF pools, whereafter a quantitative assay using three antibodies and isotope-labelled
29 standard peptides was developed.

30 In brain, full-length and a C-terminal fragment of NfL were identified. In CSF, there were at least three
31 major forms of NfL: two rod domain-containing fragments (amino acids 92-224 with some variation at
32 the C-terminus, and amino acids 324-360), as well as a C-terminal fragment containing the tail of NfL
33 (from amino acid 530 to at least 540). No N-terminal fragments were recovered and full-length NfL was
34 not detectable. These newly identified CSF NfL species were confirmed in a discovery cohort of controls
35 and AD participants (N=10), before further validating these findings in a confirmation cohort of
36 participants with AD dementia, non-AD dementia and healthy controls (N=81).

37 In agreement with previous studies using immunoassays, Budelier and colleagues showed that NfL was
38 increased in CSF from individuals with AD (symptomatic, amyloid-positive) compared with controls

1 (asymptomatic, amyloid-negative). They further demonstrated that the fold change in NfL observed
2 between groups varied depending on the NfL fragment measured, which is a very important observation
3 for projects aimed at developing clinical-grade assays for the biomarker. The highest performing
4 fragments were GMNEALEK (amino acids 324-331) and VEGAGEEQAAK (amino acids 530-540). In
5 particular, the GMNEALEK peptide from the rod domain was found to correlate the best with NfL
6 concentrations derived using the most commonly used commercial ELISA (UmanDiagnostics), suggesting
7 this specific region-targeted IP-MS assay shows the greatest promise as a candidate reference method
8 for CSF NfL.

9 Additionally, the full assay, in which multiple forms of NfL can be simultaneously quantified, will be
10 invaluable in experimental and human studies examining NfL biology and kinetics, mechanisms of
11 release and turnover, and potential disease-specific changes. Such studies are likely to further benefit
12 from the general conservation of the NfL sequence across animal species, thus requiring minimal to no
13 analytical adaption of the assay for various experimental models.

14 **Data availability**

15 Data sharing is not applicable to this article as no new data were created or analysed.

16 **Competing interests**

17 CAL reports no disclosures. HZ is a co-chair of the Alzheimer's Association Global Biomarker
18 Standardization Consortium, has served at scientific advisory boards and/or as a consultant for Abbvie,
19 Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk,
20 Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet
21 Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure,
22 Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a
23 part of the GU Ventures Incubator Program (outside submitted work).

24

References

1. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament light protein in CSF. *J Neurochem*. 1996; 67:2013-18.

2. Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic Value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. *JAMA Neurol*. 2019; 76:1035-48.

3. Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. *Neurology*. 2003; 61:1720-25.

4. Abdulle S, Mellgren Å, Brew BJ, et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. *J Neurol*. 2007; 254: 1026-32.

5. Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. *Arch Neurol*. 2006; 63:1277-80.

6. Budelier MM, He Y, Barthélemy NR, et al. A map of neurofilament light chain species in brain and CSF and alterations in Alzheimer's disease. *Brain Commun*. 2022; fcac045, https://doi.org/10.1093/braincomms/fcac045